B.Riley FBR analyst Andrew D’silva reiterated a Buy rating on Sensus Healthcare Inc (NASDAQ: SRTS) today and set a price target of $12.50. The company’s shares opened today at $6.47.
D’silva said:
“Sensus Healthcare (SRTS) reported 3Q18 results AMC yesterday, 11/1, and held a corresponding conference call at 4:30 p.m. ET. The company posted a top-line/EPS/adj. EBITDA of $6.3M/ ($0.03)/($0.1)M, which topped our/consensus estimates of $5.2M/($0.12)/($1.3)M and $5.9M/ ($0.07)/($1.1)M, respectively. The top- and bottom-line beat was largely due to the placement of additional SRT-100 Vision systems than we projected as well as lower-than-expected opex. Management continues to believe it will grow its top-line at a double-digit rate in 2018 and expects 4Q18 to continue its trend of being seasonally strong.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 15.8% and a 47.9% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Sorrento Therapeutics, and Kindred Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sensus Healthcare Inc with a $10.80 average price target, a 66.9% upside from current levels. In a report released today, Maxim Group also maintained a Buy rating on the stock with a $10 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.88 and a one-year low of $4.91. Currently, Sensus Healthcare Inc has an average volume of 88.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
